Literature DB >> 14627435

Differences in regulatory properties between human and rat glucokinase regulatory protein.

Katy J Brocklehurst1, Rick A Davies, Loranne Agius.   

Abstract

The inhibition of glucokinase by rat and Xenopus GKRPs (glucokinase regulatory protein) is well documented. We report a comparison of the effects of human and rat GKRPs on glucokinase activity. Human GKRP is a more potent inhibitor of glucokinase than rat GKRP in the absence of fructose 6-phosphate or sorbitol 6-phosphate, and has a higher affinity for these ligands. However, human and rat GKRPs have similar affinities for fructose 1-phosphate and chloride. Residues that are not conserved between the rodent and human proteins affect both the affinity for fructose 6-phosphate and sorbitol 6-phosphate and the inhibitory potency of GKRP on glucokinase in the absence of these ligands.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14627435      PMCID: PMC1223974          DOI: 10.1042/BJ20031414

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  18 in total

1.  The mechanism by which rat liver glucokinase is inhibited by the regulatory protein.

Authors:  A Vandercammen; E Van Schaftingen
Journal:  Eur J Biochem       Date:  1990-07-31

2.  Identification of fructose 6-phosphate- and fructose 1-phosphate-binding residues in the regulatory protein of glucokinase.

Authors:  Maria Veiga-da-Cunha; Emile Van Schaftingen
Journal:  J Biol Chem       Date:  2001-12-27       Impact factor: 5.157

3.  A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose 6-phosphate and fructose 1-phosphate.

Authors:  E Van Schaftingen
Journal:  Eur J Biochem       Date:  1989-01-15

4.  Evidence that glucokinase regulatory protein is expressed and interacts with glucokinase in rat brain.

Authors:  Elvira Alvarez; Isabel Roncero; Julie A Chowen; Patricia Vázquez; Enrique Blázquez
Journal:  J Neurochem       Date:  2002-01       Impact factor: 5.372

5.  Acute fructose administration decreases the glycemic response to an oral glucose tolerance test in normal adults.

Authors:  M C Moore; A D Cherrington; S L Mann; S N Davis
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

Review 6.  Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes.

Authors:  F M Matschinsky
Journal:  Diabetes       Date:  1990-06       Impact factor: 9.461

7.  Competitive inhibition of liver glucokinase by its regulatory protein.

Authors:  A Vandercammen; E Van Schaftingen
Journal:  Eur J Biochem       Date:  1991-09-01

8.  Effectors of the regulatory protein acting on liver glucokinase: a kinetic investigation.

Authors:  M Detheux; A Vandercammen; E Van Schaftingen
Journal:  Eur J Biochem       Date:  1991-09-01

9.  Species and tissue distribution of the regulatory protein of glucokinase.

Authors:  A Vandercammen; E Van Schaftingen
Journal:  Biochem J       Date:  1993-09-01       Impact factor: 3.857

10.  Mutations in the glucokinase regulatory protein gene in 2p23 in obese French caucasians.

Authors:  M Veiga-da-Cunha; J Delplanque; A Gillain; D T Bonthron; P Boutin; E Van Schaftingen; P Froguel
Journal:  Diabetologia       Date:  2003-05-09       Impact factor: 10.122

View more
  15 in total

1.  Antibodies against the voltage-dependent anion channel (VDAC) and its protective ligand hexokinase-I in children with autism.

Authors:  Mario Gonzalez-Gronow; Miguel Cuchacovich; Rina Francos; Stephanie Cuchacovich; Maria del Pilar Fernandez; Angel Blanco; Edith V Bowers; Steven Kaczowka; Salvatore V Pizzo
Journal:  J Neuroimmunol       Date:  2010-06-23       Impact factor: 3.478

2.  Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.

Authors:  Kiichiro Ueta; Tracy P O'Brien; Gregory A McCoy; Kuikwon Kim; Erin C Healey; Tiffany D Farmer; E Patrick Donahue; Audree B Condren; Richard L Printz; Masakazu Shiota
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-04-08       Impact factor: 4.310

Review 3.  Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism.

Authors:  Anne Raimondo; Matthew G Rees; Anna L Gloyn
Journal:  Curr Opin Lipidol       Date:  2015-04       Impact factor: 4.776

4.  Discovery of a novel site regulating glucokinase activity following characterization of a new mutation causing hyperinsulinemic hypoglycemia in humans.

Authors:  Nicola L Beer; Martijn van de Bunt; Kevin Colclough; Christine Lukacs; Paul Arundel; Constance L Chik; Joseph Grimsby; Sian Ellard; Anna L Gloyn
Journal:  J Biol Chem       Date:  2011-03-29       Impact factor: 5.157

Review 5.  From genetic association to molecular mechanism.

Authors:  Martijn van de Bunt; Anna L Gloyn
Journal:  Curr Diab Rep       Date:  2010-12       Impact factor: 4.810

6.  Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk.

Authors:  M G Rees; S Wincovitch; J Schultz; R Waterstradt; N L Beer; S Baltrusch; F S Collins; A L Gloyn
Journal:  Diabetologia       Date:  2011-10-25       Impact factor: 10.122

7.  Functional characterization of MODY2 mutations highlights the importance of the fine-tuning of glucokinase and its role in glucose sensing.

Authors:  Carmen-María García-Herrero; Oscar Rubio-Cabezas; Sharona Azriel; Angel Gutierrez-Nogués; Angel Aragonés; Olivier Vincent; Angel Campos-Barros; Jesús Argente; María-Angeles Navas
Journal:  PLoS One       Date:  2012-01-24       Impact factor: 3.240

8.  Identification and functional characterisation of novel glucokinase mutations causing maturity-onset diabetes of the young in Slovakia.

Authors:  Lucia Valentínová; Nicola L Beer; Juraj Staník; Nicholas D Tribble; Martijn van de Bunt; Miroslava Hučková; Amy Barrett; Iwar Klimeš; Daniela Gašperíková; Anna L Gloyn
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

9.  Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations.

Authors:  Marju Orho-Melander; Olle Melander; Candace Guiducci; Pablo Perez-Martinez; Dolores Corella; Charlotta Roos; Ryan Tewhey; Mark J Rieder; Jennifer Hall; Goncalo Abecasis; E Shyong Tai; Cullan Welch; Donna K Arnett; Valeriya Lyssenko; Eero Lindholm; Richa Saxena; Paul I W de Bakker; Noel Burtt; Benjamin F Voight; Joel N Hirschhorn; Katherine L Tucker; Thomas Hedner; Tiinamaija Tuomi; Bo Isomaa; Karl-Fredrik Eriksson; Marja-Riitta Taskinen; Björn Wahlstrand; Thomas E Hughes; Laurence D Parnell; Chao-Qiang Lai; Göran Berglund; Leena Peltonen; Erkki Vartiainen; Pekka Jousilahti; Aki S Havulinna; Veikko Salomaa; Peter Nilsson; Leif Groop; David Altshuler; Jose M Ordovas; Sekar Kathiresan
Journal:  Diabetes       Date:  2008-08-04       Impact factor: 9.461

10.  The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver.

Authors:  Nicola L Beer; Nicholas D Tribble; Laura J McCulloch; Charlotta Roos; Paul R V Johnson; Marju Orho-Melander; Anna L Gloyn
Journal:  Hum Mol Genet       Date:  2009-07-30       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.